Live
AgilentAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma - BioSpaceLonza NewsLonza opens Media Development Lab in Singapore for cell culture media optimisation - BioSpectrum AsiaIlluminaIllumina Inc. Stock: Dominant Player in Genomic Sequencing Faces Competitive and Regulatory Challeng - AD HOC NEWSEndpoints NewsTop HHS official makes impassioned pitch to take on China biotechThermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After SHL Medical Alliance And U.S. Capacity Expansion - Yahoo FinanceIlluminaA Look At Labcorp Holdings (LH) Valuation After Illumina Alliance Puts Precision Oncology In Focus - simplywall.stIlluminaDRAGEN v4.5: Expanding Accurate Variant Discovery Across the Entire Genome - IlluminaThermo FisherIs It Time To Reassess Thermo Fisher Scientific (TMO) After Recent Share Price Weakness? - simplywall.stCellSTING signaling modulation by COPII cargo recognitionCellDevelopment of non-spatial grid-like neural codes tracks inference and intelligenceFierceBiotechCMR Surgical kicks off Versius Plus robot’s US commercial launchAgilentVanguard disaggregates holdings after realignment — Agilent (NYSE: A) - Stock Titan
BioWorld Dec 22, 2025

FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM

FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM

Original
Body unavailable. Use the original source.

Directory

59 All